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Abstract
Globally, there are approximately 240 million people chronically infected with hepatitis B virus 
(HBV) – a major cause of hepatocellular carcinoma. Ten different HBV genotypes (A-J) have 
been identified with distinct geographic distributions. Novel variants generated by recombination 
between different HBV genotypes have been documented worldwide and represent an important 
element of genetic variability with possible clinical implications. Here, the complete genome 
sequence of an HBV genotype D/E recombinant from Ghana is reported. The full-length sequence 
was obtained using rolling circle amplification followed by PCR and then sequenced using next 
generation sequencing (NGS). A consensus sequence was extracted from the NGS data and 
underwent phylogenetic analysis to determine genotype, as well as the recombination pattern. 
Subsequently, the sequence was compared to recombinants described previously in Africa. Based 
on MCMC phylogenetic analysis, SimPlot recombination analyses, and intragroup genetic 
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distance, the isolate 007N full-length genome is unique compared to other reported D/E 
recombinants in Africa.
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Introduction
Hepatitis B virus (HBV) remains a global health problem with approximately 240 million 
chronically infected people and 780,000 deaths per year due to acute infections, cirrhosis of 
the liver, and hepatocellular carcinoma [1, 2]. The prevalence of HBV is highest in sub-
Saharan Africa and East Asia, where 5–10% of the adult population is chronically infected 
[1]. Hepatitis B is an enveloped, 3.2 kb partially double-stranded DNA virus, which belongs 
to the Hepadnaviridae family [3]. The virus is arranged in four overlapping open reading 
frames (ORFs): polymerase (P), surface (S), precore/core (C), and the X gene (X) [4]. Like 
retroviruses, HBV utilizes a reverse transcriptase enzyme during replication, resulting in 
high viral diversity [5].
There are ten HBV genotypes (A-J) classified by sequence divergence of at least 8% in the 
entire HBV genome [6–8]. Genotypes A-D and F have been further classified into 
subgenotypes with a genetic variation of 4–8% [9–11]. Genotypes A and D are prevalent in 
the European Union and in Central/South Asia; B and C in South/South East Asia and the 
Pacific region; E in West/Central Africa; F in South/Central America and Alaska; G and H 
in Europe and Japan; I in Vietnam and Laos; and J in Japan [11, 12].
Genotypes represent an invaluable tool for tracing the molecular evolution and transmission 
patterns of HBV [11]. Several studies suggest that clinical outcomes may be due to 
differences in pathogenic potential between genotypes [13–15]. HBV genotypes have been 
shown to differ according to the course of disease, development of mutations, and response 
to antiviral therapy [16]. Genotype determination is important in identifying patients who 
are at increased risk of disease progression and in optimizing treatment [15].
Recombination between genotypes occurs in regions where multiple genotypes co-circulate 
and facilitates diversification within individuals and in the general population. Novel 
variants generated by recombination between different HBV genotypes have been 
documented worldwide [17–21]. In West Africa, one or more A/B, A/C, A/E, C/E, D/E, and 
D/E/A recombinants have been identified [5, 22, 23]. Recombination is an important 
element of HBV genetic variability with possible clinical implications [24, 25]. The research 
reported here was aimed at further investigating an HBV variant from Ghana whose initial 
partial sequence was identified as a possible recombinant.
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Methods
Patient Information
The newly identified recombinant is from a HIV-HBV coinfected, 52 year-old male from 
Northern Ghana who was previously enrolled in two cross-sectional studies. At the time of 
sample collection in 2013, he was antiretroviral treatment-naïve with an unknown CD4+ 
count, hepatitis B e-antigen negative, e-antibody positive, and had HBV DNA of 84,060,683 
IU/mL. The original study investigated the proportion and factors associated with hepatitis B 
viremia in treatment-experienced and treatment-naïve HIV co-infected Ghanaians [26]. A 
subsequent sub-study examined HBV resistance mutations [27]. Phylogenetic analysis from 
this resistance study grouped the genotype D patient (sample 007N) with three D/E 
recombinants from Niger (FN594768-71), although it include only a 1,004 bp fragment 
corresponding to the HBV reverse transcriptase region. Because genotype D is relatively 
uncommon in West Africa and to determine if this variant was, in fact, a D/E recombinant, 
the entire full-length genome was analyzed.
Next-Generation Sequencing
HBV DNA was extracted from 500 uL of patient serum using the QIAamp UltraSens Virus 
Kit (QIAGEN, Valencia, CA, USA), and the full-length sequence was obtained using rolling 
circle amplification followed by PCR [18]. DNA-seq was performed by the Genomics, 
Epigenomics and Sequencing Core (GESC) at the University of Cincinnati. The PCR 
product was transferred to a microTUBE (Covaris, Woburn, MA) and sheared with the 
Covaris S2 focused-ultrasonicator. The sample was prepared for the sequencing library using 
the PrepX DNA Library kit, Apollo 324 NGS automatic library prep system (WaferGen, 
Fremont, CA), and a ChIP-seq script. The ligated library was indexed and enriched by 6 
cycles of PCR using sample-specific index and universal PCR primers, followed by 
automated AMPure XP bead purification (Beckman Coulter, Brea, CA). Equal-amount (ng) 
libraries determined by Nanodrop were pooled, diluted, and qPCR quantified with NEBNext 
Library Quant Kit (New England Biolabs, Ipswich, MA) using ABI 9700HT real-time PCR 
system (Lifetech, Grand Island, NY).
The quantified pooled library was used for cluster generation in the cBot system (Illumina, 
San Diego, CA). A library at the final concentration of 16 pM was clustered onto a flow cell 
using Illumina TruSeq SR Cluster kit v3 and sequenced for 50 cycles using TruSeq SBS kit 
on Illumina HiSeq system. A total of 445,497 reads (51 bp each) were collected and 
imported into CLC Genomic Workbench 9 for quality control and consensus assembly. 
366,512 (75.5%) reads passed the initial quality import filter. A consensus sequence was 
extracted from 348,145 (94.9%) of the remaining reads using the de novo assembler module 
v1.3 and complete HBV reference genomes from GenBank. The reads excluded from the 
consensus sequence did not meet the similarity cut off (similarity fraction set to 0.80) and 
only mapped to a small portion of the HBV genome.
Sequence Alignment & Bayesian Markov Chain Monte Carlo Analysis
The consensus sequence from this novel HBV variant was aligned with full-length 
references in ClustalX 2.1 [28]. Additional phylogenetic inference was performed using a 
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Bayesian Markov chain Monte Carlo (MCMC) approach as implemented in the BEAST 
v1.8.0 program [29] under an uncorrelated log-normal relaxed molecular clock and the 
general time-reversible model with nucleotide site heterogeneity estimated using a gamma 
distribution. The initial MCMC analysis was run for a chain length of 500,000,000 with 
sampling every 50,000th generation. Results were visualized in Tracer v1.5 to confirm chain 
convergence, and the effective sample size (ESS) was calculated for each parameter. All ESS 
values were >1,000 indicating sufficient sampling. The maximum clade credibility tree was 
selected from the posterior tree distribution after a 10% burn-in using TreeAnnotator v1.8.0. 
An additional MCMC analysis was conducted using all recombinant sequences, genotype E 
references, and subgenotype D7-D10 references and a chain length of 200,000,000.
Recombination Analysis & Intragroup Genetic Distance
To identify possible recombination, bootscanning analysis of full-length sequences was 
performed in SimPlot version 3.5.1 using the Kimura 2-parameter with a 300 base pair (bp) 
window, a 30 bp step increment, and 1,000 bootstrap replicates [30]. The full-length HBV 
sequence was compared to consensus sequences generated using full-length GenBank 
references for HBV genotypes A-H. If >80  % of the permuted trees showed similarity to 
more than one genotype, the “parental” sequences were retained within a second 
bootscanning analysis along with the consensus Pan troglodytes sequence as an outlier. To 
eliminate the possibility of a dual infection, the full-length consensus sequence was aligned 
with a second sequence amplified by targeted PCR and Sanger sequencing [27]. Despite the 
use of different amplification and sequencing methods, the consensus sequences were 
identical, indicating that the patient was not infected with multiple HBV genotypes. 
Intragroup genetic distances were calculated by pairwise comparison of nucleotide 
sequences using the Kimura 2-parameter method of Molecular Evolutionary Genetics 
Analysis (MEGA) v7.0.18 [31, 32]. The complete genome of patient 007N was deposited in 
GenBank under the accession number KU711666.
Results
Bayesian Markov Chain Monte Carlo Analysis
The phylogenetic analyses included 13 full-length D/E recombinant references from 
different regions in Africa including Niger (FN594767, FN594768, FN594769, FN594770, 
and FN594771), Sudan (KU736916 and KU736917), Ethiopia (KU736914 and KU736915), 
Kenya (KP168420 and KP168421), Ghana (GQ161754), and Gabon (GU177079). As shown 
in Figure 1, all recombinants from East Africa grouped together, and most of the 
recombinants from West Africa – excluding GU177079, FN594767, and 007N – grouped 
together. D/E recombinant sequences – regardless of their country of origin – were most 
closely related to subgenotype D7 sequences but did not form a single monophyletic group.
A subsequent MCMC analysis was conducted focusing specifically on the D/E recombinant 
references, isolate 007N, genotype E references, and subgenotype D7-D10 references 
(Figure 2). All but three of the D/E recombinants – GU177079, FN594767, and 007N – 
clustered together. The D/E recombinant from Gabon (GU177079) clustered with the 
subgenotype D7 strains from Ireland, Central African Republic, the Netherlands, and 
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Tunisia. The E/D recombinant from Niger (FN594767) clustered with the genotype E 
references. The isolate of interest – 007N – clustered with a different group of D7 references 
from Tunisia, as well as D7 strains from Belgium, Cuba, and Venezuela. There are multiple 
clusters of D7 reference strains – some grouping with known D/E recombinants and others 
grouping with D10 reference strains from Ethiopia. Thus, subgenotype D7 is not a well-
defined monophyletic cluster based on the limited sequence data available currently.
Intragroup Genetic Distance
Table 1 shows the mean genetic distance among all D/E recombinants including 007N. The 
mean genetic distance was 3.72%, with a range of 0.26% to 7.50%. All 14 full-length D/E 
recombinants were distinct from one another, with only one recombinant from Sudan and 
two from Ethiopia (KU736917, KU736914, and KU736915) having a genetic distance of 
less than 1% between them. Sequence 007N was most closely related to the other D/E 
recombinant from Ghana (GQ161754) with a genetic distance of 2.23%. The sequence from 
Niger (FN594767) had the genetic distance farthest from 007N at 7.50%. Among all the D/E 
recombinants, the most similar were the two recombinants from Ethiopia with a genetic 
distance of 0.26%, while the most divergent – aside from FN594767 and 007N – were 
FN594767 from Niger and FN594770 from Niger at 7.50%.
Recombination Analysis
All D/E recombinant sequences – including the 13 references and 007N – were analyzed 
further in SimPlot to determine recombination patterns. The bootscans of each recombinant 
were created using all full-length genotype D7 and E references used in the MCMC analysis 
with the full-length Pan troglodytes sequence as an outlier. Bootscans with a genome map to 
illustrate where the recombination breakpoints are located within the circular HBV genome 
are shown in Figure 3.
Seven of the 14 sequences – KU736914-17, FN594768, FN594771, and GQ161754 – have a 
breakpoint between nt 1,100–1,200 (located in the P ORF) where >80% of permuted trees 
showed a shift from genotype D to genotype E. With the exception of sequence FN594767, 
all the recombinants showed a shift from genotype D to genotype E between nt 1,700–2,400 
corresponding to the P, X, and C ORFs. Eleven recombinants from Kenya, Ethiopia, Sudan, 
Niger, and Ghana – KP168420-21, KU736914-17, FN594768-71, and GQ161154 – have an 
additional breakpoint between nt 2,900–3,100 which is located in the S and P overlapping 
ORF. One of the Niger samples – FN594767 – has a unique recombination pattern compared 
to other D/E recombinants with only one breakpoint between nt 500–900 in which >80% of 
permuted trees show a shift from genotype D to genotype E. There is a breakpoint between 
nt 900–1,100 – as seen in Fig. 3(g) – where the sequence shifts back from genotype E to 
genotype D, although the percentage of permuted trees is ~75%. This recombinant is 
referred to in its original publication as an E/D recombinant because a majority of the 
sequence data is similar to genotype E [33].
The reference recombinant from Gabon and 007N – Fig. 3(m) and 3(n) – both have only one 
breakpoint above 80%. Thus, the two sequences from Ghana – Fig. 3(l) and 3(n) – have 
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distinctly different recombination patterns despite GQ161754 being the closest reference 
sequence to 007N based on genetic distance.
Discussion
Over 400 complete HBV intergenotypic recombinant genomes have been identified around 
the world [34]. HBV genotypes can help elucidate the transmission patterns of HBV because 
variants have a distinct geographic distribution genotype. Overall, intergenotypic 
recombinants exhibit similar circulation patterns as their original genotypes [34]. Hepatitis B 
virus genotype A is predominant in South/East Africa, D in North Africa, and E in West/
Central Africa [12]. Genotype E hybrids are generally found in African countries with A/E 
recombinants in Cameroon, Ghana, and Guinea [35, 36] and D/E recombinants in Gabon, 
Ghana, Niger, Sudan, Kenya, and Ethiopia [33, 35, 37, 38]. There are two documented E 
hybrids reported from France (A/E) and Ireland (D/E); however, both involve patients 
originating from Africa [18, 39].
When all full-length intergenotypic recombinant genomes were compared, the majority 
(73%) consisted of HBV variants with identical recombination sites [34]. Similar breakpoint 
locations among several sequences occur due to recombination hot spots or a single 
ancestral recombination event circulating within a population. An analysis of breakpoint 
positions was conducted on 117 sequences with different breakpoints and/or genotype 
composition. Favored recombination sites were identified within nt 1,700–1,900, nt 1,800–
2,000, and nt 2,100–2,300 [34]. Isolate 007N from this study has two breakpoints which 
span these favored recombination sites between nt 1,700–2,400. The other D/E recombinants 
analyzed in this study share this breakpoint and have an additional breakpoint between nt 
1,100–1,200.
Based on the MCMC phylogenetic analysis, SimPlot recombination analysis, and intragroup 
genetic distance calculations, the isolate 007N full-length genome is unique compared to 
other reported D/E recombinants in Africa. As shown in Figures 1 and 2, isolate 007N – as 
well as other published, full-length D/E recombinant strains – clustered with HBV 
subgenotype D7. This may indicate that the D/E recombinants are more specifically D7/E 
recombinant strains. However, this conclusion cannot be confidently drawn from the data 
available given that multiple clusters of subgenotype D7 sequences were observed in Figure 
2. Despite many of the subgenotype D7 strains coming from the same country of origin, they 
did not form a monophyletic group, suggesting that the D7 subgenotype is not accurately 
defined to date and requires further analysis of additional samples from a wider geographic 
distribution of patients.
Available data on HBV genotypes and their effect on disease profile are currently limited to 
specific genotypes – mostly A, B, C, and D. However, evidence suggests that HBV 
genotypes and subgenotypes play a critical role in host-viral interactions. Knowledge of 
HBV genotype will enable clinicians to determine patients’ response to treatment and their 
risk of future complications [13–15]. More expansive epidemiological and in vitro studies 
are needed to better understand the pathogenic effects of all HBV genotypes. These data 
would then help to determine if HBV genotype D differs from genotype E in its 
Boyce et al. Page 6
Virus Genes. Author manuscript; available in PMC 2017 December 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
recombinogenic potential and/or if a particular recombinant HBV genotype differs from a 
non-recombinant HBV genotype in terms of pathogenic mechanisms and patient outcomes.
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Figure 1. 
Bayesian phylogenetic tree of 87 full-genome HBV sequences generated with BEAST 
v1.8.0. The sample of interest is denoted as “007N”, while reference sequences are labeled 
“genotype – accession number – country of origin”. All reported recombinants are marked 
with an asterisk after their genotype designation, and relevant posterior values are shown.
Boyce et al. Page 9
Virus Genes. Author manuscript; available in PMC 2017 December 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 2. 
Bayesian phylogenetic tree of 68 full-genome HBV sequences generated with BEAST 
v1.8.0. Genotype E, subgenotype D7, subgenotype D8, subgenotype D9, subgenotype D10, 
and genotype D/E recombinant reference sequences are included. The sample of interest is 
denoted as “007N”, while reference sequences are labeled “genotype – accession number – 
country of origin”. All reported recombinants are marked with an asterisk after their 
genotype designation, and relevant posterior values are shown.
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Figure 3. 
Bootscan analysis of reference (a) KP168420, (b) KP168421, (c) KU736914, (d) 
KU736915, (e) KU736916, (f) KU736917, (g) FN594767, (h) FN594768, (i) FN594769, (j) 
FN594770, (k) FN594771, (l) GQ161154, (m) GU177079, and (n) sample 007N 
(KU711666) using the Kimura 2-parameter with a 300 base pair (bp) window, a 30 bp step 
increment, and 1,000 bootstrap replicates.
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